The Health Burden of Cancer Attributable to Obesity in Korea: A Population-Based Cohort Study. by 源��깭�쁽 et al.
│ https://www.e-crt.org │ 933Copyright ⓒ 2019 by  the Korean Cancer Association
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cancer Res Treat. 2019;51(3):933-940
pISSN 1598-2998, eISSN 2005-9256
https://doi.org/10.4143/crt.2018.301
Open Access
The Health Burden of Cancer Attributable to Obesity in Korea: 
A Population-Based Cohort Study
Original Article
Purpose
Considering the health impact of obesity and cancer, it is important to estimate the burden
of cancer attributable to high body mass index (BMI). Therefore, the present study attempts
to measure the health burden of cancer attributable to excess BMI, according to cancer
sites.    
Materials and Methods
The present study used nationwide medical check-up sample cohort data (2002-2015).
The study subjects were 496,390 individuals (268,944 men and 227,446 women). We
first calculated hazard ratio (HR) in order to evaluate the effect of excess BMI on cancer 
incidence and mortality. Then, the adjusted HR values and the prevalence of excess BMI
were used to calculate the population attributable risk. This study also used the Global Bur-
den of Disease method, to examine the health burden of obesity-related cancers attributable
to obesity. 
Results
The highest disability-adjusted life year (DALY) values attributable to overweight and obesity
in men were shown in liver cancer, colorectal cancer, and gallbladder cancer. Among
women, colorectal, ovarian, and breast (postmenopausal) cancers had the highest DALYs
values attributable to overweight and obesity. Approximately 8.0% and 12.5% of cancer
health burden (as measured by DALY values) among obesity-related cancers in men and
women, respectively, can be prevented.
Conclusion
Obesity has added to the health burden of cancer. By measuring the proportion of cancer
burden attributable to excess BMI, the current findings provide support for the importance
of properly allocating healthcare resources and for developing cancer prevention strategies
to reduce the future burden of cancer. 
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Introduction
Cancer a major cause of mortality and morbidity world-
wide and is expected to increase sharply with global aging
and increasing cancer incidence [1]. Cancer is still the pri-
mary cause of death since 1983, with about one million can-
cer patients and with about 220,000 new cancer cases and
74,000 cancer deaths annually [2,3]. Furthermore, according
to the International Agency for Research on Cancer’s GLO-
BOCAN report, Korea’s 5-year cancer prevalence rate (1,523
per 100,000) is more than twice the international prevalence
rate (625 per 100,000) [4]. Population aging, progress of treat-
ment, and cancer screening programs are increasing both the
incidence and the survival rate of cancer [5].  
When targeting a particular population, the burden of dis-
ease can be measured as the difference between an ideal
health level and the actual health level. The health burden of
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disease can be measured by several indicators, including
mortality, incidence, prevalence, health-adjusted life expec-
tancy (HALE), disability-adjusted life years (DALYs), qual-
ity-adjusted life years (QALYs), and Healthy Life years
(HeaLYs) [6]. Mortality, incidence, and prevalence are the
most basic indices, but these indicators do not include infor-
mation about quality of life. These traditional indicators of
disease burden do not reflect improvements in health condi-
tions since the illness. Another way to measure the burden
of disease is to measure the burden of disease with a health
index that takes into account quality of life (QOL), which is
measured as an indicator of disease status and death com-
bined. The World Health Organization (WHO) and the Glo-
bal Burden of Disease (GBD) Study Group developed the
DALYs indicator in order to reflect both time of disability
and time lost due to premature death [7]. The reason for 
estimating the burden of disease using various methods is
that the measurement of the burden of disease helps to 
improve health care decision-making by improving the allo-
cation of healthcare resources and the assessment of the 
effects of health-related interventions.
The WHO has defined obesity as a disease and has pre-
dicted that it will become a health problem as important as
smoking in the 21st century, with a 2014 survey showing that
the worldwide obesity prevalence in 2014 had doubled com-
pared to in 1980 [8]. The prevalence of obesity in Korea has
increased from 26.2% of men and 25.1% of women in 1998 to
34.7% of men and 27.3% of women in 2005, and 35%-39% of
men and 23%-28% of women have been maintained until 
recently.
There have been many studies on obesity and cancer in
Korea [9-11]. Most studies have estimated the burden of can-
cer using cancer incidence or mortality, which do not reflect
patients’ QOL [12-14]. On the other hand, we used DALYs
to evaluate the health burden of cancer which reflects pati-
ents’ QOL. DALYs evaluate health differences that combine
life lost due to disability and premature death. Comprehen-
sive information using DALY can help to quantify the bur-
den of obesity-related cancer and allocate health care resour-
ces. In addition, most studies that have estimated the relative
risk of cancer given the presence of obesity have not reflected
other confounding variables [14,15]. Furthermore, studies
about obesity and cancer risk have not reflected recent
changes in the prevalence of obesity and the increasing epi-
demiological changes in cancer risk. The most recent repre-
sentative large cohort study in Korea, the postmenopausal
Korean women study and the Korean Cancer Prevention
Study, were followed up to 2003 and 2006, respectively. Since
then, there has been no representative cohort study of obesity
and cancer burden in recent years [16-18]. Therefore, the
present study aims to examine the health burden of obesity-
related cancers attributable excess body mass index (BMI) by
using nationwide cohort sample data using the GBD method.
Considering the health impact of obesity and cancer, it is 
important to measure the burden of cancer, taking into 
account recent epidemiological changes.
Materials and Methods
1. Study population and design
This study used medical check-up nationwide sample 
cohort data from National Health Insurance Service (NHIS)
claims in 2002 and 2015. The medical check-up cohort data
included demographic, socioeconomic, and mortality-related
information as well as information about medical utilization,
hospital characteristics, and health check-ups. The data 
included approximately 10% of all participants who received
a general health check-up as of 2002-2003, aged 40-79 in 2002,
a total of 514,866 Koreans (279,125 men and 235,741 women).
This study used 514,866 populations who received a general
health check-up in 2002-2003, aged 40-79. Of these, the par-
ticipants who were diagnosed with cancer (n=17,335) or died
(n=686) during 2002-2003 were excluded. In addition, we 
excluded participants whose BMI data at baseline were miss-
ing (n=455). Ultimately, the study population comprised
496,390 individuals (268,944 men and 227,446 women). 
2. Variables
To analyze the health burden of cancer attributable to over-
weight or obesity, we examined DALYs of obesity-related
cancers attributable to excess BMI as outcome variables
(Table 1). The DALY measure includes both the years of life
lost (YLL) to premature death and years lived with disability
(YLD). To quantify the burden of cancer patients, the WHO
and the GBD developed DALY. It measures the difference
between current health and ideal status as an index of years
of healthy life lost. Disability weights, discounting, and age-
weighting of DALYs were used in this study.
The development of cancer was defined according to the
first cancer admission event using the 10th version of the 
International Classification of Disease codes in admission
records, and cancer mortality was defined as death by cancer
using cause of death information in Statistics Korea, after 
excluding cancer cases and deaths during first 2 years. In 
addition, obesity-related cancer types were identified by the
International Agency for Research on Cancer (IARC), the
World Cancer Research Fund (WCRF), and the American 
Institute for Cancer Research (AICR) [19-21]. There is suffi-
cient evidence that overweight or obesity increases the risk
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of esophageal, colorectal, pancreatic, post-menopausal brea-
st, endometrial, kidney, and liver cancers. On the other hand,
cancer sites with limited evidence for a link to obesity include
gallbladder, ovarian, and advanced prostate cancers (S1 Table).
The primary interesting variable is BMI. The most fre-
quently used measure of underweight, overweight, and
obese is BMI. It was calculated as height and weight obtained
from medical check-up (weight [kg]/height [m2]) and cate-
gorized as underweight (BMI < 18.5 kg/m2), normal (18.5-
22.9 kg/m2), overweight (23-24.9 kg/m2), obese (25-29.9 kg/
m2), and severely obese (! 30 kg/m2). Cancer risk factors 
including BMI used were not updated from baseline medical
check-up in this analysis. 
Other independent variables are demographic and socioe-
conomic variables (sex, age, income level), health check-up
variables (smoking status, drinking, physical activity, family
history of cancer, total cholesterol), and medical utilization
variables (Charlson comorbidity index [CCI], regular use of
aspirin). Smoking status was classified as never smoker, for-
mer smoker, and current smoker. Alcohol consumption was
categorized as non-drinker (no alcohol consumption), mod-
erate drinker (up to 14 drinks for men and up to 7 drinks for
women per week), or heavy drinker (15 drinks or more for
men and 8 drinks or more for women per week). Physical 
activity was categorized as never, less than 3 days per week,
3 to less than 5 days per week, or more than 5 days per week.
CCI score is helpful to predict 1-year mortality. The comor-
bid condition is assigned to 1, 2, 3, or 6 depending on comor-
bidity’s severity. Several studies have shown that the use of
aspirin is associated with reduced risk of overall cancer
[22,23]. The U.S. Preventive Services Task Force recommen-
ded the use of aspirin for primary prevention of colorectal
cancer [24]. Regular use of aspirin was defined as aspirin use
at least 2 times per week. Family history of cancer was asked
with biennial questionnaire. Only gynecological cancer was
adjusted for oral contraceptive (OC) and hormone replace-
ment therapy (HRT) use. In case of OC and HRT, because the
risk of cancer decreases rapidly after cessation of use, we
used OC and HRT of one year prior to the onset of cancer
[25].
3. Statistical analysis
Chi-square and t test were performed to assess the differ-
ences in characteristics according to cancer incidence and
mortality. To calculate the population attributable risk (PAR),
the basic formula is the following Levin’s formula:
, where RRi is the relative risk and is pi prevalence of risk fac-
tor. 
On the other hand, as BMI category is divided into five cat-
egories, more sophisticated method is regarded to calculate
PAR of excess BMI as follows:
, where RRow, RRo, and RRso are the adjusted-relative risk of
cancer for overweight, obesity, and severe obesity respec-
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Table 1. Data sources and formulas for DALYs
YLL, years of life lost; YLD, years lived with disability; DALY, disability-adjusted life year. 
DALYs Data source
YLL
YLL=M!{[KCera/(r+!)2][e–(r+!)(L+a)[–(r+!)(L+a)–1]–e–(r+!)a[–(r+!)a–1]]+[(1–K)/r](1–e–rL)} [26]
Average age at onset for each age cohort (a) Average age
Discount rate (r=0.03) [26]
Age-weighting constants (!=0.04, K=1.00, C=0.1658) [26]
Mortalities (M)
Standard life expectancy at the age of death (L) [27]
YLD
YLD=I!DW!{[KCera/(r+!)2][e–(r+!)(L+a)[–(r+!)(L+a)–1]–e–(r+!)a[–(r+!)a–1]]+[(1–K)/r](1–e–rL)} [26]
Incidences (I)
Disability weights (DW) [28]
Average age at onset for each age cohort (a)
Discount rate (r=0.03) [26]
Age-weighting constants (!=0.04, K=1.00, C=0.1658) [26]
Expected duration of disability (L)
∑pi (RRi–1)PAR=
∑pi (RRi–1)+1
∑pow (RRow–1)+∑po (RRo–1)+∑pso (RRso–1)PAR=
∑pow (RRow–1)+∑po (RRo–1)+∑pso (RRso–1)+1
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tively, and pow, po, and pso are prevalence of overweight, obe-
sity, and severe obesity respectively. To estimate the adjusted-
relative risk, we first performed Cox proportional hazard
model to evaluate the effect of excess BMI on cancer inci-
dence and mortality, adjusting confounding variables and
stratifying sex and cancer type.
To evaluate the health burden of cancer patients attributa-
ble to obesity in Korea, we estimated DALYs as the sum of
the YLL and YLD. To estimate YLL, the cancer mortality and
standard life expectancy were used. To estimate YLD, cancer
incidence, average duration of cancer, and disability weight
were used (Table 1).
4. Ethical statement
This study was approved by the Institutional Review
Board of Yonsei University Severance Hospital (Y-2017-
0032). The informed consent was waived.
Results
The study population characteristics at baseline (2002-
2003) are shown in S2 Table. Table 2 shows hazard ratio [HR]
for BMI category and obesity related-cancer sites which is
confirmed by IARC, WCRF and AICR. Among cancer types
examined in this study, colorectal and kidney cancers had
significantly high HR estimates for cancer incidence in men
(colorectal, BMI 25.0-29.9 kg/m2: HR, 1.02; 95% confidence
interval [CI], 0.94 to 1.10; BMI ! 30.0 kg/m2: HR, 1.28; 95%
CI, 1.04 to 1.56; kidney, BMI 23.0-24.9 kg/m2: HR, 1.25; 95%
CI, 1.00 to 1.56; BMI 25.0-29.9 kg/m2: HR, 1.36; 95% CI, 1.10
to 1.68). Obesity was significantly associated with risk for
mortality from kidney, prostate, colorectal, liver, and gall-
bladder cancers (kidney, BMI ! 30.0 kg/m2: HR, 3.85; 95%
CI, 1.34 to 11.03; prostate, BMI 25.0-29.9 kg/m2: HR, 1.50; 95%
CI, 1.07 to 2.09; BMI ! 30.0 kg/m2: HR, 2.87; 95% CI, 1.15 to
7.14; colorectal, BMI 25.0-29.9 kg/m2: HR, 1.38; 95% CI, 1.14
to 1.68; BMI ! 30.0 kg/m2: HR, 2.28; 95% CI, 1.37 to 3.81; liver,
BMI 25.0-29.9 kg/m2: HR, 1.25; 95% CI, 1.09 to 1.44; BMI 
! 30.0 kg/m2: HR, 2.03; 95% CI, 1.43 to 2.89; gallbladder, BMI
25.0-29.9 kg/m2: HR, 1.32; 95% CI, 1.00 to 1.74; BMI ! 30.0
kg/m2: HR, 2.00; 95% CI, 1.02 to 3.93).
HR for BMI category and cancer in women is shown in
Table 3. Endometrial cancer had the highest HR estimate for
cancer incidence in women (BMI 25.0-29.9 kg/m2: HR, 1.77;
95% CI, 1.28 to 2.45; BMI ! 30.0 kg/m2: HR, 3.81; 95% CI, 2.32
to 6.23). Other cancer sites with significant HR estimates for
cancer incidence were breast (postmenopausal), liver, gall-
bladder, colorectal, ovary, kidney, pancreas in women (breast,
BMI ! 30.0 kg/m2: HR, 1.85; 95% CI, 1.48 to 2.29; liver, BMI
25.0-29.9 kg/m2: HR, 1.44; 95% CI, 1.26 to 1.64; BMI ! 30.0
kg/m2: HR, 1.55; 95% CI, 1.18 to 2.03; gallbladder, BMI 25.0-
29.9 kg/m2: HR, 1.26; 95% CI, 1.03 to 1.54; BMI ! 30.0 kg/m2:
HR, 1.50; 95% CI, 1.02 to 2.19; colorectal, BMI 25.0-29.9
kg/m2: HR, 1.24; 95% CI, 1.12 to 1.36; BMI ! 30.0 kg/m2: HR,
1.24; 95% CI, 1.02 to 1.52; ovary, BMI 25.0-29.9 kg/m2: HR,
1.39; 95% CI, 1.14 to 1.70; kidney, BMI 25.0-29.9 kg/m2: HR,
1.37; 95% CI, 1.11 to 1.69; pancreas, BMI 25.0-29.9 kg/m2: HR,
1.31; 95% CI, 1.09 to 1.57). Liver cancer had a significant HR
estimate for cancer mortality in women (BMI 25.0-29.9 kg/
m2: HR, 1.46; 95% CI, 1.13 to 1.89; BMI ! 30.0 kg/m2: HR, 2.01;
95% CI, 1.25 to 3.23).
The prevalence of BMI category according to sex and age
group is shown in S3 Table. Table 4 shows the population 
attributable fraction (PAF) of obesity by cancer types. Over-
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Men Women
PAF (%) Cases PAF (%) Deaths PAF (%) Cases PAF (%) Deaths
Colorectal 1.4 78 13.7 123 11.5 364 11.0 48
Liver 4.5 201 11.9 204 19.5 332 22.2 100
Gallbladder 3.0 27 17.1 77 10.3 71 10.1 33
Pancreas 1.0 11 7.0 46 11.0 91 5.9 23
Breast: postmenopausal 18.6 554 5.1 9
Endometrial 34.0 101 - -
Ovary 17.0 132 - -
Prostate 1.2 78 18.7 54
Kidney 16.4 133 15.8 21 15.5 59 18.7 8
% of all cancers 1.4 5.5 7.1 6.3
Table 4. Estimated number of cancer cases and deaths attributable to overweight and obesity
PAF, population attributable fraction. 
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weight and obesity were responsible for 528 cancer inci-
dences (1.4%) and 525 cancer deaths (5.5%) in men. Among
women, 1,704 cancer incidences (7.1%) and 222 cancer deaths
(6.3%) were attributable to overweight and obesity.
Table 5 shows YLL, YLD, and DALY attributable to over-
weight and obesity by cancer site, during the follow-up 
period. DALYs of cancer attributable to overweight and obe-
sity were 1,740 person-years per 100,000 (8.0%) in men and
2,373 person-years per 100,000 (12.5%) in women. The cancer
sites with the highest DALY values among men were liver,
colorectal, and prostate cancers (liver, 6,989.3 person-years
per 100,000; colorectal, 6,494.2 person-years per 100,000;
prostate, 3,764.5 person-years per 100,000). Among women,
colorectal, ovarian, and breast (postmenopausal) cancers had
the highest DALY values (colorectal, 4,440.6 person-years per
100,000; ovary, 3,345.3 person-years per 100,000; breast,
3,240.2 person-years per 100,000).
Discussion
To evaluate the burden of cancer attributable to excess BMI
in Korea, we estimated the DALYs by obesity-related cancer
types identified by IARC, WCRF, and AICR. According to
the results of the study, colorectal and kidney cancers had
the highest HR estimates for cancer incidence in men. 
Endometrial, post-menopausal breast, liver, gallbladder, col-
orectal, ovarian, kidney, and pancreas cancers had significant
HR estimates for cancer incidence in women. Similar to the
cancer statistics from the Korea Central Cancer Registry
(KCCR) in 2014, in this study the age-standardized cancer 
incidence rate among the obesity-related cancer types was
highest in colorectal and liver cancers among men and in
breast and colorectal cancers among women [29]. With 
regard to the age-standardized cancer mortality rate, accord-
ing to KCCR liver and colorectal cancers among men and col-
orectal, liver, and breast cancers among women were high-
est. Although the absolute values were different because of
different subjects and units, the results were similar when
comparing this study’s ranks for cancer types with those of
KCCR.
The findings of this study were similar to those of previous
studies concerning obesity and cancer risk. Reeves et al.
(2007) [30] was conducted on British women recruited into
the Million Women Study, aged 50-64 in 1996-2001, and they
were followed until 2004. Endometrial cancer, adenocarci-
noma of the esophagus, and kidney, pancreatic, ovarian,
breast, and colorectal cancers had significant HR estimates
for cancer incidence in postmenopausal women. The results
of the current study and those of the Million Women Study
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showed similar trends, except that HR values of pancreas
and kidney cancer were different because the number of 
severely obese people was small in this study. Jee et al. (2008)
[17] analyzed the HR of BMI and cancer in Korean men and
women, aged 30-95, who participated in National Health 
Insurance Corporation (NHIC) health examinations in 1992-
1995, following the study population until 2006. High BMI
was significantly associated with risk for colon, liver, and
gallbladder cancers in men and for liver, gallbladder, pan-
creatic, and postmenopausal breast cancers in women. Song
et al. (2008) [16] examined BMI and cancer using a cohort of
postmenopausal Korean women who participated in NHIC
medical evaluations from 1993 to 1994; they were followed
up until 2003. Colorectal, gallbladder, breast, corpus uteri,
and kidney cancers had significant HR estimates for cancer
incidence in postmenopausal women. 
The results of this study show the health burden of obe-
sity-related cancer attributable to obesity. Compared with
previous studies about obesity-related cancer health burden,
the PAF values of this study are lower than in other studies.
But careful interpretation of direct comparison with other 
research results is required, because there are differences 
between the studies of obesity-related cancer types included
in the analysis. An extensive study in Europe showed that
the overall proportions of cancer attributable to excess BMI
in European were 3% in men and 6% in women, while those
of the current study were 1.4% and 7.1%, respectively [31].
The attributable proportions by countries were 2.1% for
Greece men, 4.9% for Germany men, 3.9% for Denmark
women, and 8.8% for Spain women. The attributable propor-
tions by cancer type in men and women were 4.4% for
prostate, 8.5% for breast, 39.2% for endometrium, 25.5% and
24.5% for kidney, and gallbladder 24.8% and 23.7%, respec-
tively. Compared to the European, proportions attributable
to excess BMI were lower for prostate, endometrium, kidney,
and gallbladder (prostate, 1.2%; endometrium, 34.0%; kid-
ney, 16.4% in men, 15.5% in women; gallbladder, 3.0% in
men, 10.3% in women) and higher for breast (18.6%) in the
current study. WCRF reported that the PAF of high BMI in
cancer incidence in 2012 were 20.8% for North America,
17.2% for Western Europe, and 6.0% for East Asia among
men; however, in the results of the current study the figure
was 1.4% for Korean men [32]. With regard to women, the
figures were 14.2% for North America, 14.5% for Western 
Europe, and 8.3% for East Asia, respectively; on the other
hand, in the results of the current study the figure for Korean
women was 7.1%. Because the age ranges of subjects were
different, the estimates might be different when comparing
the attributable burden by cancer types as found in this study
with the results of other studies. In addition, the differences
of the current study results which were greater from Western
countries than from Asian countries might be expected, as
the risks of several obesity related-cancers are different by
ethnic groups and obesity prevalence in Asian populations
is lower than that in Western populations [13,32].
The present study has several limitations. First, the HR val-
ues may be uncertain because the HR values were analyzed
for 10% of the participants who received a health checkup in
the specified year, not the HR values for the whole popula-
tion. However, this study used large scale and representative
cohort data with confounding variables such as income level,
smoking status, alcohol drinking, physical activity, family
history of cancer, total cholesterol, comorbidity, and regular
use of aspirin. Adjusting these confounders could reduce the
uncertainty of the relative risk value. Second, this study used
BMI determined during the baseline health check-up and did
not update the BMI. It is known that it takes about 10-20
years between exposure and cancer development. However,
since this cohort data contains 14-year follow-up data, BMI
changes after baseline were not available. Nevertheless, BMI
was calculated by height and weight measured in health
screenings, not by self-reported height and weight. Third, as
the data did not contain information about cancer stages, this
study could not consider cancer severity, which affects dis-
ability and medical expenses. Sixth, the study also lacks data
about postmenopausal status. Nevertheless, since the asso-
ciation between obesity and breast cancer varies according
to menopausal status, women over 55 years of age were con-
sidered postmenopausal women for the purposes of this
study. The median age of menopause in Korean women is
50, and 95% are menopausal before the age of 55 [33].
This study found that the DALYs of cancer due to obesity
were 2,373.2 person-years per 100,000 in men and 1,740.2 per-
son-years per 100,000 in women, accounting for 8.0% and
12.5%, respectively, of the health burden of obesity-related
cancers. Considering that obesity increases the burden of
cancer and the prevalence of obesity is increasing, further 
efforts are needed to reduce obesity rates. These updated 
results about the health impact of obesity on cancer provide
useful data to help determine how best to allocate healthcare
resources and how best to develop cancer prevention strate-
gies to reduce the burden of cancer.
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